Denise Loring is a partner in Ropes & Gray's Intellectual Property Group and practices in the area of complex intellectual property litigation. Denise joined Ropes & Gray in 2005 when it merged with IP boutique Fish & Neave, where she had been a partner since 1991. Denise has extensive experience as lead counsel in hi-stakes patent litigation, in both U.S. federal and international courts. Denise is a co-author of the Model Patent Jury Instructions of the American Bar Association and a co-author of Patent Depositions, Chapter 13 in Patent Litigation Strategies Handbook (2d ed. 2005). Denise is a frequent lecturer and has spoken recently on topics that include biosimilars legislation, patent eligibility of methods patents and isolated DNA sequences, the proposed patent reform legislation and the use of demonstrative exhibits and graphics in expert testimony at trial.
- Shelbyzyme v. Genzyme (D. Del.). Denise is lead counsel in this biotech case defending Genzyme's life-saving drug, Fabrazyme®, against charges of patent infringement.
- AstraZeneca v. Apotex (D. NJ). In 2009, Denise and her team obtained a preliminary injunction, barring a generic drug company from an at-risk launch of a generic version of our client’s pediatric asthma drug.
- AstraZeneca v. Ivax (D. NJ). In this case involving inhalation medication for the treatment of asthma, the District Court granted a motion brought by Denise and her team for a temporary restraining order. The case settled favorably before commencement of a preliminary injunction hearing.
- AstraZeneca v. Mayne Pharma (S.D.N.Y.). Denise was lead counsel in this case involving an injectable emulsion anesthetic. The District Court entered judgment for our client that its patents were valid, enforceable and infringed after a two-week bench trial in March 2005. The Federal Circuit affirmed.
- Cancer Research Technology Limited and Schering Corp. v. Barr (D. Del.). In this case involving medication for the treatment of malignant glioma, the District Court entered judgment for Barr; the Federal Circuit reversed, confirming the validity and enforceability of out clients’ patent.
- Purdue v. Endo (S.D.N.Y.). This case involved patents on Purdue’s OxyContin® controlled-release pain medication. An eleven-day bench trial resulted in judgment that Purdue’s patents were infringed, but unenforceable. On appeal, the Federal Circuit reversed the judgment of unenforceability and affirmed infringement. The case settled favorably.
- Wyeth v. Sandoz (D. Del.). Denise represents Wyeth in this pending ANDA case involving antibiotic compounds and compositions.
Honors & Awards
©1996-2012 Ropes & Gray LLP. All rights reserved.
|
|
Education
-
JD, New York University School of Law, 1982
-
MS (Molecular Biology), Albert Einstein College of Medicine of Yeshiva University, 1978
-
BS (Biological Sciences), with Honors, Stony Brook University, 1976
Bar Admissions
- New York
- U.S. Patent and Trademark Office
Courts
- U.S. Court of Appeals for the Federal Circuit
- U.S. District Court for the Eastern District of New York
- U.S. District Court for the Southern District of New York
Memberships & Affiliations
- American Bar Association
- American Intellectual Property Law Association
- Federal Circuit Bar Association
- New York Intellectual Property Law Association
|
|